Indeed, researchers are looking for inhibitors of NOX2 as a novel therapeutic class of drugs to treat diseases such as AD, PD, cardiovascular diseases, and many other diseases where oxidative stress and inflammation are key drivers. Here, CYBB is linked to Parkinson disease.